Condition (MeSH)
Gastrinoma
ClinicalTrials.gov lists 35 trials for Gastrinoma or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 6.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
35 of the 35 trials are tagged with Gastrinoma itself; the rest are tagged with a narrower condition beneath it.
When did Gastrinoma trials start? (19)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 2/3
- Phase 3
- Not applicable
- Observational
Top of scale: 4
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2023 | 1 |
| 2018 | 1 |
| 2016 | 1 |
| 2014 | 3 |
| 2013 | 1 |
| 2012 | 1 |
| 2009 | 1 |
| 2008 | 1 |
| 2007 | 1 |
| 2006 | 2 |
Showing 10 of 19 earlier years.
No forecast is made for this condition: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 35 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Gastrinoma trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 21 |
| Phase 2/3 | 1 |
| Phase 3 | 2 |
| Not applicable | 1 |
| Observational | 3 |
How many Gastrinoma trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Active, not recruiting | 1 |
| Completed | 23 |
| Terminated | 7 |
| Withdrawn | 3 |
| Unknown status | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Gastrinoma trials? (6)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 6 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 4 |
| ECOG-ACRIN Cancer Research Group | 2 |
| Eastern Cooperative Oncology Group | 2 |
| Novartis Pharmaceuticals | 2 |
Showing 5 of 6 sponsors.
Which drugs are being tested for Gastrinoma? (5)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| "Capecitabine" | 4 |
| EVEROLIMUS | 3 |
| Calcium Leucovorin | 3 |
| OXALIPLATIN | 2 |
| Vatalanib | 2 |
Interventions as named in the registry (10)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| LAR Octreotide | 3 |
| SOC: Temozolomide | 3 |
| Fluorouracile | 2 |
| Bevacizumab 1 | 2 |
| combined chemotherapy with streptozotocin, 5-fluorouracil, and doxorubicin | 1 |
Showing 5 of 10 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
How do Gastrinoma trials deliver against plan? (1)
Shown in this order: one row, this condition's own record. Enrollment hit target: the share of trials mapped to this condition whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 1 of 4 hit target (n=4); 31 of 35 trials not graded | 1 of 3 on time (n=3); 32 of 35 trials not graded |
Delivery grades from ClinicalTrials.gov / AACT (CTTI) planned-vs-actual history, public domain.
Which serious adverse events do Gastrinoma trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Abdominal pain | 29 | 5 |
| Fatigue | 29 | 4 |
| Nausea | 25 | 5 |
| Vomiting | 20 | 5 |
| Diarrhea | 17 | 5 |
Showing 5 of 10 adverse events.
Which publications cover Gastrinoma? (4)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Current diagnosis and management of Zollinger-Ellison syndrome. | Annals of surgery | 1989 | Yes |
| Multiple endocrine neoplasia type 1: duodenopancreatic tumours. | Journal of internal medicine | 2003 | No |
| Multiple endocrine neoplasia type 1 in patients with recognized pituitary tumours of different types. | Clinical endocrinology | 1997 | No |
| Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2. | Gut | 1996 | No |
Not on this page
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.